CN117716031B - 使用dkc1进行rna编辑的组合物、系统和方法 - Google Patents

使用dkc1进行rna编辑的组合物、系统和方法

Info

Publication number
CN117716031B
CN117716031B CN202280037916.7A CN202280037916A CN117716031B CN 117716031 B CN117716031 B CN 117716031B CN 202280037916 A CN202280037916 A CN 202280037916A CN 117716031 B CN117716031 B CN 117716031B
Authority
CN
China
Prior art keywords
gsnorna
dkc1
protein
sequence
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202280037916.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN117716031A (zh
Inventor
张美芳
伊成器
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ruiyu Beijing Biopharmaceutical Co ltd
Ruiyu Beijing Biopharmaceutical Technology Co ltd
Original Assignee
Ruiyu Beijing Biopharmaceutical Co ltd
Ruiyu Beijing Biopharmaceutical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ruiyu Beijing Biopharmaceutical Co ltd, Ruiyu Beijing Biopharmaceutical Technology Co ltd filed Critical Ruiyu Beijing Biopharmaceutical Co ltd
Publication of CN117716031A publication Critical patent/CN117716031A/zh
Application granted granted Critical
Publication of CN117716031B publication Critical patent/CN117716031B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/52—Isomerases (5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
CN202280037916.7A 2021-05-26 2022-05-26 使用dkc1进行rna编辑的组合物、系统和方法 Active CN117716031B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021096122 2021-05-26
CNPCT/CN2021/096122 2021-05-26
PCT/CN2022/095172 WO2022247896A1 (en) 2021-05-26 2022-05-26 Compositions, systems and methods of rna editing using dkc1

Publications (2)

Publication Number Publication Date
CN117716031A CN117716031A (zh) 2024-03-15
CN117716031B true CN117716031B (zh) 2025-12-05

Family

ID=84228426

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280037916.7A Active CN117716031B (zh) 2021-05-26 2022-05-26 使用dkc1进行rna编辑的组合物、系统和方法

Country Status (9)

Country Link
US (1) US20240238394A1 (cg-RX-API-DMAC10.html)
EP (1) EP4347834A4 (cg-RX-API-DMAC10.html)
JP (1) JP7902855B2 (cg-RX-API-DMAC10.html)
CN (1) CN117716031B (cg-RX-API-DMAC10.html)
AU (1) AU2022280907A1 (cg-RX-API-DMAC10.html)
CA (1) CA3219203A1 (cg-RX-API-DMAC10.html)
IL (1) IL308565A (cg-RX-API-DMAC10.html)
TW (1) TW202307205A (cg-RX-API-DMAC10.html)
WO (1) WO2022247896A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024259332A2 (en) * 2023-06-16 2024-12-19 The University Of Chicago Methods and compositions for regulating gene expression
TW202504646A (zh) * 2023-06-16 2025-02-01 北京大學 利用環狀rna抑制無義介導的降解的系統和方法
WO2025119204A1 (en) * 2023-12-04 2025-06-12 Modit Therapeutics Beijing Limited Methods and compositions for improved readthrough of pseudouridine-modified codons
CN121380197B (zh) * 2025-12-22 2026-04-24 北京大学 基于假尿苷修饰的rna单碱基编辑系统及方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112020557A (zh) * 2018-03-27 2020-12-01 罗切斯特大学 用于假尿苷化的核酸分子

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989911A (en) * 1997-05-09 1999-11-23 University Of Massachusetts Site-specific synthesis of pseudouridine in RNA
US8603457B2 (en) * 2005-12-02 2013-12-10 University Of Rochester Nonsense suppression and genetic codon alteration by targeted modification
US20210340197A1 (en) * 2018-08-31 2021-11-04 The Regents Of The University Of California Directed pseudouridylation of rna

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112020557A (zh) * 2018-03-27 2020-12-01 罗切斯特大学 用于假尿苷化的核酸分子

Also Published As

Publication number Publication date
AU2022280907A1 (en) 2023-11-16
WO2022247896A1 (en) 2022-12-01
TW202307205A (zh) 2023-02-16
JP7902855B2 (ja) 2026-08-10
US20240238394A1 (en) 2024-07-18
CN117716031A (zh) 2024-03-15
IL308565A (en) 2024-01-01
CA3219203A1 (en) 2022-12-01
JP2024519733A (ja) 2024-05-21
EP4347834A4 (en) 2025-05-21
EP4347834A1 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
US12037602B2 (en) Methods and compositions for modulating a genome
US20240417757A1 (en) Methods and compositions for modulating a genome
US20230242899A1 (en) Methods and compositions for modulating a genome
US12031162B2 (en) Methods and compositions for modulating a genome
WO2022247896A1 (en) Compositions, systems and methods of rna editing using dkc1
WO2023039440A9 (en) Hbb-modulating compositions and methods
US20230053353A1 (en) Targeting transfer rna for the suppression of nonsense mutations in messenger rna
US20240374759A1 (en) Methods and compositions for modulating a genome
CN112020557A (zh) 用于假尿苷化的核酸分子
US20230348939A1 (en) Methods and compositions for modulating a genome
WO2024073385A2 (en) Synthetic polypeptides and uses thereof
WO2024137767A1 (en) Compositions and methods for modifying dux4
WO2025119204A1 (en) Methods and compositions for improved readthrough of pseudouridine-modified codons
IL323067A (en) Compositions and methods of serpina modulators
WO2025265017A1 (en) Ass1 gene insertion for the treatment of citrullinemia type i
WO2025193808A1 (en) Cns-specific gene replacement therapy for genetic forms of als/ftd

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: China

Address after: Room 101, Building B, Innovation Building, No. 29 Shengshengyuan Road, Changping District, Beijing 102206, Beijing Dart International Innovation Platform K115

Applicant after: Ruiyu (Beijing) Biopharmaceutical Technology Co.,Ltd.

Address before: 101, Building B, Innovation Building, No. 29 Shengshengyuan Road, Changping District, Beijing, 102200. Beijing Dart International Innovation Platform K115

Applicant before: Ruiyu (Beijing) Biopharmaceutical Co.,Ltd.

Country or region before: China

GR01 Patent grant
GR01 Patent grant